CTRI/2019/01/017214已完成4 期
A Prospective, Single arm, Multicentre, Post-marketing Study (Phase IV) to evaluate safety and efficacy of Dr. Reddy�s Trastuzumab (DRL_TZ) in Patients with HER2-Positive Cancer.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Established histopathologically/cytologically confirmed diagnosis of HER2 positive breast cancer (early or metastatic) or metastatic gastric cancer with documented evidence of either IHC3+ or IHC2+ with fluorescence in situ hybridization (FISH) positivity;
- •2. Eligible to receive DRL_TZ treatment for EBC or MBC or MGC
排除标准
- •1. Male patients with breast cancer
研究者
相似试验
招募中
4 期
A Study to Assess the Safety and Performance of Balloon Catheter in Superficial Femoral and Popliteal ArteriesCTRI/2024/03/063744Sahajanand Medical Technologies Limited
招募中
4 期
Study to evaluate the safety and efficacy of Ovine Forestomach Matrix (OFM) products in acute or chronic wound.CTRI/2022/01/039714Aroa Biosurgery Limited
招募中
4 期
Assessment of the clinical outcome of Bioabsorbable Ligament Anchor used in treatment of Shoulder Rotator Cuff Repair.CTRI/2022/06/043248Chetan Meditech Pvt Ltd
已完成
4 期
A scientific Study to understand the effect ofMebeverine Hydrochloride 135 mg and Chlordiazepoxide 5 mg Tablets in Indian Patientwith Management of Irritable Bowel SyndromeCTRI/2020/09/027980Abbott India Ltd60
已完成
4 期
To evaluate the safety and effectiveness of Anafortan® syrup (Camylofin Dihydrochloride 12.5 mg plus Paracetamol IP 125 mg) in Indian children presenting with acute colicky i.e. spasmodic abdominal pain.CTRI/2018/10/015902Abbott Healthcare Limited197